What Will Happen to Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Next? The Stock Has Increase in Shorts – The Lamp News

Investors sentiment decreased to 1.5 in Q2 2019. Its down 0.21, from 1.71 in 2019Q1. It is negative, as 5 investors sold Actinium Pharmaceuticals, Inc. shares while 5 reduced holdings. 6 funds opened positions while 9 raised stakes. 23.11 million shares or 171.36% more from 8.52 million shares in 2019Q1 were reported.Hartford Management has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Pnc Fin Services Group has 1.03 million shares for 0% of their portfolio. Da Davidson has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Northwestern Mutual Wealth Mgmt has 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Malaga Cove Cap Lc holds 30,000 shares. Intrust Bancshares Na has 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 40,000 shares. Two Sigma Secs Limited Liability Company invested in 26,352 shares or 0% of the stock. Cetera Advisor has invested 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Fosun Intl holds 0.01% or 596,752 shares. 10,000 are owned by Baker Ellis Asset Management Ltd Liability Corporation. Renaissance Limited Liability Com, a New York-based fund reported 211,628 shares. Sabby Mngmt Ltd reported 2.58% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Susquehanna Intl Gru Llp invested in 0% or 70,048 shares. Natl Bank Of America De holds 0% or 3,284 shares. Sns Grp Inc Limited Com reported 35,000 shares.

The stock of Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) registered an increase of 10.57% in short interest. ATNMs total short interest was 4.06M shares in October as published by FINRA. Its up 10.57% from 3.67 million shares, reported previously. With 1.56 million shares average volume, it will take short sellers 3 days to cover their ATNMs short positions.

The stock increased 5.95% or $0.0119 during the last trading session, reaching $0.212. About 482,193 shares traded. Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has declined 63.91% since October 20, 2018 and is downtrending. It has underperformed by 63.91% the S&P500.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company has market cap of $34.43 million. The companys proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. It currently has negative earnings. The Companys lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.

More notable recent Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) news were published by: Streetinsider.com which released: Form 8-K Actinium Pharmaceuticals For: Oct 18 StreetInsider.com on October 18, 2018, also Prnewswire.com with their article: Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting PRNewswire published on June 04, 2019, Finance.Yahoo.com published: Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment Yahoo Finance on September 16, 2019. More interesting news about Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) were released by: Prnewswire.com and their article: Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers PR Newswire published on October 01, 2018 as well as Finance.Yahoo.coms news article titled: Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa Yahoo Finance with publication date: September 30, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:
What Will Happen to Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Next? The Stock Has Increase in Shorts - The Lamp News